Tariq Musa sold $17K of GH
Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $149.56 on 2026-11-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides incremental transparency on director ownership but does not introduce new company fundamentals, guidance, or regulatory/clinical catalysts.
Market read
Traders may note the insider sale for sentiment monitoring, but the 10b5-1 framing and small dollar amount suggest limited trading impact.
What to watch
The sale size is small relative to typical institutional flows, and the plan is pre-arranged, which often means the timing is not information-driven.
Background
The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported from SEC EDGAR.
Ticker impact
Guardant Health director Tariq Musa sold 116 shares at $149.56 on 2026-11-16 under a pre-arranged 10b5-1 plan, totaling $17,348.96.
Likely limited price impact; any reaction should fade as the transaction is explicitly tied to a pre-arranged 10b5-1 plan.
The filing is a small, director-level open-market sale with stated 10b5-1 pre-arrangement, which usually reduces interpretive weight versus discretionary selling.
Market effects
Minimal spillover to biotech/diagnostics peers; this is an individual insider transaction, not a sector catalyst.
No clear regional market linkage beyond US small-to-mid cap sentiment.
Low global relevance; no cross-border deal, regulation, or supply-chain shock described.
Counterpoint
Even with 10b5-1, repeated insider selling can be interpreted by some traders as a mild caution signal about near-term outlook.
Key entities
- issuerGuardant Health, Inc.
US-listed company whose director insider sale is disclosed via SEC Form 4.
- insiderTariq Musa
Director who sold 116 shares under an open-market transaction code S, dated 2026-11-16.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan noted as Yes, which typically reduces information content of the sale timing.

